- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05486975
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0591CP Cell in Patients With Relapsed and/or Refractory Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Chengcheng Fu
- Phone Number: 13962191404
- Email: fuzhengzheng@suda.edu.cn
Study Contact Backup
- Name: Jingjing Shang
- Phone Number: 180 1356 8250
- Email: rebeccasjj@163.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Recruiting
- First Affiliated Hospital, SooChow University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients and legally acceptable representative must have voluntarily signed ICF and willing to complete the study procedure, after fully understanding of the study.
- Age ≥ 18 years and ≤ 75 years, male or female.
- The patients have received at least 3 prior regimens for MM.
- Subjects should have received treatment with at least one proteasome inhibitor and one immunomodulatory drug (IMiD; and have been stable disease, relapsed or progressed after treatment with at least one regimen consisting of above-mentioned medications.
- Subjects should have relapsed within 12 months after the last line of therapy, or not achieved at least minimal response (MR) or disease has progressed within 60 days after last line of therapy, with documented evidence.
- Subjects should have measurable disease per IMWG 2016 criteria serum M-protein or urine M-protein are not measurable.
1) Serum M protein ≥ 5 g / L; 2) 24-hour urinary M-protein ≥ 200 mg; 3) The serum free light chain (sFLC) ratio was abnormal and the involved FLC ≥ 100mg/L in patients with light chain multiple myeloma whose serum or urinary M protein levels did not meet the assessable criteria.
7. Expected survival > 12 weeks. 8. Eastern Cooperative Oncology Group (ECOG) scores 0 - 1. 9. Subjects should have adequate function in hemostatic and liver and kidney. 10. Women of childbearing age must undergo a serum pregnancy test with negative results at screening and before lymphodepletion and be willing to use an effective and reliable method of contraception for at least 1 year after T cell infusion. All female subjects are prohibited from egg donation within 1 year after T cell infusion.
11. Men must be willing to use an effective and reliable method of contraception for at least 1 year after T cell infusion if they have sexual activity with women of childbearing potential. All male subjects are prohibited from sperm donation within 1 year after T cell infusion.
Exclusion Criteria:
- Pregnant or lactating women.
- Subjects positive for any following tests: human immunodeficiency virus (HIV) antibody, Treponema pallidum (syphilis) antibody, hepatitis C virus (HCV) antibody,
- Active hepatitis B; HBV-DNA test must be below the lower limit of measurement.
- Subjects with any uncontrolled active infection (Except for prophylactic treatment).
- Subjects with AEs from previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ 1, excluding hair loss and other events that the treating physician considers as tolerable.
- Subjects who have received autologous BCMA CAR-T therapy
- Subjects who have had anti-BCMA therapy.
- Subjects who have received allogeneic stem cell transplantation for MM.
- Subjects who have received autologous stem cell transplantation less than 12 weeks before ICF.
- Positive anti-HLA-II antibody specificity test
- Subjects who have received any anti-MM treatment 14 days before ICF; the subjects are eligible to participate in the study regardless of the radiotherapy end date if the radiation area less than 5% of whole body.
- Subjects who have received systemic glucocorticoids within 7 days before infusion, except inhaled steroids.
- Subjects who have Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome or primary light chain amyloidosis.
- Subjects who have been received live attenuated vaccine within 8 weeks or inactivated vaccine within 4 weeks before lymphodepletion.
- Subjects allergic to or intolerant of fludarabine, cyclophosphamide, tocilizumab, or allergic to the ingredients (DMSO) of CT0591CP cell preparations; subject with confirmed another serious allergy history.
- Subjects who have any uncontrolled disease conditions within 6 months prior to the signing of inform consent.
- LVEF < 50%
- Blood oxygen saturation that can only be maintained at > 95% by oxygen inhalation.
- Subjects known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other conditions that require long-term immunosuppressive therapy.
- Subjects with second malignancies in addition to MM are not eligible if the second malignancy has required treatment within the past 5 years
- Subjects who have central nervous system (CNS) metastases or symptomatic CNS involvement.
- Subjects who are unable or unwilling to comply with the requirements of clinical trial or other reasons that are not suitable for participating in the clinical trial.
- Subjects who have received major surgery 2 weeks prior to ICF or plan to receive major surgery within 4 weeks after cell infusion (excluding cataract and other local anesthesia).
- Subjects who are related to investigator or study personnel, or with possible conflict of interest with the investigator or study personnel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: 21-28 days post administration of CT0591CPcells
|
dose limiting toxicity
|
21-28 days post administration of CT0591CPcells
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CT0591CP-CG6018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and/or Refractory Multiple Myeloma
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Clinical Trials on CT0591CP Cells
-
Medical College of WisconsinMiltenyi Biomedicine GmbHActive, not recruitingB-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin LymphomaUnited States
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
Hadassah Medical OrganizationCompletedAmyotrophic Lateral Sclerosis
-
American CryoStem CorporationTerminatedMultiple SclerosisCayman Islands
-
UNC Lineberger Comprehensive Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingNeoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Hodgkin DiseaseUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingNeoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-HodgkinUnited States
-
The Second Affiliated Hospital of Fujian Medical...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaUnknown
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
University of PennsylvaniaActive, not recruitingRefractory Acute Lymphoblastic Leukemia | Chemotherapy Resistant Acute Lymphoblastic LeukemiaUnited States